基础医学与临床2011，Vol.31Issue(1)：19-24,6.
厄罗替尼联合塞来昔布阻断EGFR和COX-2抑制肺癌A549细胞增殖
Erlotinib combined with celecoxib inhibits the growth of lung cancer A549 cells by simultaneously blocking EGFR and COX-2
摘要
Abstract
Objective To explore the effects of erlotinib combined with celecoxib on apoptosis and the expression of epidermal growth factor receptor (EGFR) and cycloo xygenase-2 ( COX-2 ) in lung cancer A549 cells.Methods A549 cells were observed under an inverted microscope, MTT was used to measure the growth inhibitory effects of A549 cells by erlotinib and celecoxib.The cell apoptosis was examined by TUNEL and Hoechst33258 staining method.The cell cycle was detected by flow cytometer, and the expression of EGFR, COX-2 were determined by immunofluorescence.Results A huge amount of granules and vacuolus were observed in the combined treatment A549,with cell rounding and defluxion (P ＜ 0.05 ).The combination increased apoptosis of A549 (P ＜ 0.05 ) and significantly induced G1 phase arrest ( P ＜ 0.05 ) and down-regulated expression of EGFR, COX-2 in A549 cells ( P ＜ 0.05 ).Conclusion Combination therapy with erlotinib and celecoxib showed significant synergistic inducing apoptosis and Gt phase arrest, that is explained by down-regulating expressing both EGFR and COX-2.关键词
厄罗替尼/塞来昔布/A549细胞/表皮生长因子受体/环氧合酶-2Key words
erlotinib/ celecoxib/ A549 cell/ epidermal growth factor receptor/ cyclooxygenase-2分类
医药卫生引用本文复制引用
白小燕,牟晓燕,姜淑娟,王亚丽,刘庆亮..厄罗替尼联合塞来昔布阻断EGFR和COX-2抑制肺癌A549细胞增殖[J].基础医学与临床,2011,31(1):19-24,6.基金项目
山东省自然科学基金(ZR2009CM125) （ZR2009CM125）
